rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Dermata Therapeutics, Inc.

DRMA · Nasdaq

Health CareBiotechnologyNot moving yet

DRMA stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 30.1% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$2,540
Insider sales, 12 months
$26
Officials’ trades on record
0
Institutions holding
13 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2,448Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months1
Buyers · sellers1 · 1
WhoDidSharesTraded
Kathleen D. ScottDirectorsold11at $1.1916 Jun 2026filed 16 Jun 2026
Munera Maria E. Bedoya-ToroSVP, Regulatory Affairsbought1,000at $1.2717 Feb 2026filed 17 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders13+6 on the quarter
New · exited7 · 1
Reported value$158K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202620,203$26K-28,131−58.2%
Welch & Forbes LLCunchanged · filed 30 Jul 202620,000$26K00.0%
STATE STREET CORPnew · filed 7 Aug 202618,747$24K+18,747
UBS Group AGreduced · filed 13 Aug 202616,796$22K-18,812−52.8%
SUSQUEHANNA INTERNATIONAL GROUP, LLPnew · filed 14 Aug 202615,989$21K+15,989
XTX Topco Ltdnew · filed 14 Aug 202614,787$19K+14,787
Advisory Alpha, LLCnew · filed 11 Aug 202610,000$13K+10,000
Tower Research Capital LLC (TRC)added · filed 11 Aug 20263,860$4,979+3,144+439.1%
MCF Advisors LLCunchanged · filed 12 Aug 20261,732$2,23500.0%
BARCLAYS PLCnew · filed 14 Aug 2026270$348+270
30 Jun 2023 – 30 Jun 2026
81623Jun 23Mar 24Dec 24Sep 25Jun 26

Everyone who traded it

Gerald T. Proehl Company insiderPRESIDENT, CHAIRMAN, CEO · last 16 Aug 20263 · 0
Kyri K. Van Hoose Company insiderSVP, CFO · last 16 Aug 20260 · 0
Kathleen D. Scott Company insiderDirector · last 16 Jun 20260 · 1
Munera Maria E. Bedoya-Toro Company insiderSVP, Regulatory Affairs · last 17 Feb 20261 · 0
Andrew Seth Sandler Company insiderDirector · last 2 Jan 20260 · 0
Brittany Bradrick Company insiderDirector · last 2 Jan 20260 · 0
Christopher J. Nardo Company insiderSenior VP, CDO · last 2 Jan 20260 · 0
David F. Hale Company insiderDirector · last 2 Jan 20261 · 0
Mary Fisher Company insiderDirector · last 2 Jan 20260 · 0
Steven J. Mento Company insiderDirector · last 2 Jan 20260 · 0
Wendell Wierenga Company insiderDirector · last 2 Jan 20260 · 0
Proehl Investment Ventures Llc Company insider10% owner · last 17 Aug 20210 · 0

Same industry

MRNA ModernaLeading+167%
IOVA Iovance BiotherapeuticsLeading+141%
ABCL AbCellera BiologicsLeading+57%
ENTX Entera BioLeading+52%
HALO Halozyme TherapeuticsLeading+48%
XERS Xeris Biopharma HoldingsLeading+47%
XNCR XencorLeading+41%
HELP Helus PharmaLeading+39%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 25 Mar 202651.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.5M

Analyst forecasts

No analyst forecasts yet.